Exclusive negotiation period for trofinetide outside North America

Melbourne, Australia, 26 October 2018: Neuren Pharmaceuticals (ASX: NEU) today reported that Neuren and ACADIA Pharmaceuticals have entered a period of exclusive negotiations regarding the rights to develop and commercialize trofinetide in territories outside North America. Under the terms of the recently executed licence agreement for North America, Neuren granted ACADIA a right of first negotiation for other territories, which has now been exercised. This exclusive negotiation period will expire on 31 January 2019.

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for neurodevelopmental and neurodegenerative disorders and brain injury. Neuren has completed Phase 2 development of trofinetide for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs in Rett syndrome and Fragile X syndrome have each been granted Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Neuren has granted an exclusive license to ACADIA Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, whilst retaining all rights to trofinetide outside North America. In addition, Neuren is advancing the pre-clinical development of its second drug candidate NNZ-2591.

Contact:
Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com; +61 417 520 509

Forward-looking Statements
This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.